Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback